Current-versus-proposed rule tracker
Record the official source, publication date, operative or proposed status, covered activity, relevant effective or comment milestones, and open issues. A headline is not treated as a transaction prohibition.
Reviewed: 2026-11-03
Current policy status
As of November 3, 2026, Treasury’s October 22 COINS implementation update is a proposed rule (NPRM). Proposed biotechnology coverage must not be described as an already effective blanket ban. Check current 31 CFR Part 850 separately from the proposal and any later final rule. Section 1260H list status, procurement provisions, and restrictions on certain lobbying relationships are separate legal mechanisms.
Decision-ready outputs
Investment and ownership matrix
Organize U.S.-person nexus, transaction type, target activities, ownership, technology, and funding flows. Counsel assesses scope, exceptions, prohibitions, and notification questions separately from CFIUS analysis of inbound U.S. investment.
1260H and engagement gate
Verify the current official list and exact entity identity, then record applicable contract clauses and restrictions affecting lobbying relationships. No restricted contact or representation is undertaken before qualified counsel clears the client and proposed activity.
First 72 hours
0–24 hours
Confirm the entity, business objective, deadline, actual request, and current counsel. Agree a safe channel before sharing sensitive records.
24–48 hours
Verify the official provision, identity, operative-versus-proposed status, and supporting facts. Mark legal, technical, or scientific questions for the appropriate specialist.
48–72 hours
Prepare the issue matrix, evidence index, first stakeholder Q&A, and an approval-gated plan. This is a preparation milestone, not an agency response or decision deadline.
Choose the required role
Typical roles, not a ranking or a claim about any specific competitor.
| Provider | Role | Typical deliverable | Boundary |
|---|---|---|---|
| Large public affairs firm | Multi-issue policy and stakeholder execution | Policy campaign and engagement plan | Team, jurisdiction and actual mandate vary |
| Law firm / specialist counsel | Legal advice and representation | Legal opinion, filing, agreement | Communications execution needs an agreed scope |
| SIC Group public affairs | Evidence, policy context and stakeholder preparation | Source index, decision brief, Q&A | No legal representation or guaranteed result |
Questions before engagement
Are all proposed biotech restrictions already effective?
No. Treasury’s October 22, 2026 update is proposed. Current Part 850 requirements, the proposal, and any later final rule and effective dates must be distinguished.
Is 1260H the same as the OFAC SDN List?
No. Authorities and consequences differ. Verify the exact entity and the provisions governing the transaction, contract, or activity.
Can you lobby for every listed company?
No blanket commitment is possible. Certain lobbying relationships may be restricted. U.S. counsel must assess client identity, applicable restrictions, and the proposed activity first.
What starts the review?
Parties, ownership, U.S. nexus, technology or business category, contract or customer concern, deadline, and current counsel. Start with a non-sensitive summary.
Official sources
- Treasury: COINS proposed rule, October 22, 2026
- Treasury: Outbound Investment Program
- Defense: CLEAR lobbying relationship resources
Start with a short mandate summary
Describe your entity, objective, deadline, and current advisers. Do not include patient data, export-controlled material, or detailed trade secrets in an initial inquiry.
Contact the team